


Annual Report Brief PATIENT OUTCOMES

Ideal Option provides low-barrier treatment to people struggling with substance use disorder.









States



Ideal Option's Treatment Works.

Lab testing results¹ for patients who remained in Ideal Option's treatment program and stayed on their prescribed medications show:

Treatment Works²





use



less methamphetamine use

Life Improves³



Reported improvement in employment Ideal Option has been providing evidence-based treatment for substance use disorder using FDAapproved medications - the gold standard in addiction treatment - for more than 10 years.

Self-reported outcomes gathered via survey of over 1,800 Ideal Option patients after a minimum of 6 months of treatment show:



96% Report their quality of life has improved



93% Report no visits to the **ER for drug-related** medical care since starting treatment

96% Report no drugrelated arrests or charges since starting treatment



98% Report they feel confident in their ability to **remain in** recovery long-term



67% patients who returned for a second visit remained in treatment after 6 months

²The reduction in positive tests for all patients during 2023 at the Maintenance B Stage of Care compared to at the Initiation Stage of Care

INITIATION

New patients, re-start patients, or patients not yet stabilized on buprenorphine.





STABILIZATION A

starting to feel stable

on buprenorphine and

have reduced their use

Patients who are

of opioids.

Stages of Care

STABILIZATION B

Patients who are stable on buprenorphine and have stopped use of opioids but may still be using other nonprescribed substances.

1 Visit Every

FFKS

MAINTENANCE A


Patients who are completely stable on buprenorphine and abstinent from all nonprescribed substances.

L Visit Every


MAINTENANCE B

Patients who have long-term stability on buprenorphine and are abstinent from all nonprescribed substances.





Average Positive Rates by Stage of Care



⁴ Medication adherence refers to the positive test result for norbuprenorphine, the metabolite of buprenorphine.

idealoption.com 1-877-522-1275 ² The Census by Stage of Care as of 12/31/2023 was 15,945 patients.

For more outcomes data and to download the full annual report, visit idealoption.com/patient-outcomes